Global Development Lead (GDL), Clinical Development

About the role

We are seeking an experienced oncology drug-development leader to serve as Global Development Lead (GDL) for one of Revolution Medicines' most advanced clinical programs. This is a senior, program-accountable leadership role with end-to-end ownership of clinical development strategy and execution for a late-stage asset, including pivotal studies, regulatory engagement, and long-range planning. The GDL functions as the single point of clinical accountability for the assigned program, setting direction, driving alignment across functions, and representing the program at internal governance bodies and externally with investigators, key opinion leaders, and global health authorities. This position sits at the Executive Director level within Clinical Development and carries program-level accountability and authority typically associated with the most senior clinical leaders in the organization. In addition to program ownership, the GDL serves as a senior clinical advisor to development leadership, contributing perspective to cross-program and enterprise-level development discussions as appropriate.

Responsibilities

• Program & Clinical Strategy
• Own and lead the global clinical development strategy for the assigned program, integrating scientific, clinical, regulatory, biomarker, and commercial considerations.
• Develop and maintain the Target Product Profile (TPP), Clinical Development Plan (CDP), risk assessments, scenario analyses, and long-range program roadmap.
• Present strategic recommendations to internal governance bodies (e.g., DRG, SMT, PRG, ePRG) and drive high-quality, timely program decision-making.
• Ensure strategy reflects deep disease-area insight, emerging science, competitive intelligence, and evolving regulatory expectations.
• Execution & Oversight
• Accountable for the design, execution, and delivery of pivotal and registration-enabling studies (Phase 2/3), including protocol strategy, enrollment and geographic planning, patient safety oversight, and data interpretation.
• Ensure alignment and harmonization across related studies within the program and across regions to support coherent regulatory and lifecycle objectives.
• Provide senior clinical leadership across functions to anticipate risk, resolve complex issues, and ensure delivery of critical milestones, leveraging matrixed teams rather than direct operational control.
• Guide preparation of regulatory briefing materials and serve as the senior clinical representative in global health authority interactions.
• Scientific & Medical Leadership
• Serve as the program's senior medical authority, providing deep expertise in pancreatic and colorectal cancers.
• Translate scientific, translational, and biomarker insights into actionable clinical strategy.
• Engage key opinion leaders, investigators, advisory boards, and external experts to refine development strategy and strengthen scientific and clinical positioning.
• Cross-Functional & Enterprise Leadership
• Serve as the clinical and strategic leader for the assigned program, with clear accountability for clinical direction and integrated decision-making across functions.
• Lead a high-performing, cross-functional Global Development Team , in close partnership with the PTL or LCL, ensuring clarity of direction, strong collaboration, and accountability for outcomes.
• Demonstrate the ability to lead through both influence and authority in situations where program priorities cut across functions, senior leaders, and organizational boundaries.
• Partner with Medical Affairs and Commercial colleagues to ensure alignment between clinical strategy and future market needs.
• Act as a visible senior leader within Clinical Development, modeling enterprise mindset and contributing to broader discussions on development strategy, standards, and best practices beyond the assigned program.
• People Leadership & Organizational Impa

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience